Contact: Katherine Lazarski Press Officer[removed]removed] New report finds dramatic variations in FDA approval times

First Page		Document Content
Date: 2014-04-23 09:43:36 Medicinal chemistry Pharmaceutical industry Clinical pharmacology Food and Drug Administration Therapeutics United States Public Health Service Drug development Criticism of the Food and Drug Administration Priority review voucher Pharmacology Pharmaceutical sciences Clinical research		Contact: Katherine Lazarski Press Officer[removed]removed] New report finds dramatic variations in FDA approval times Add to Reading List Source URL: www.manhattan-institute.org Download Document from Source Website File Size: 281,51 KB Share Document on Facebook

	Federal Register / Vol. 83, NoFriday, March 16, Proposed Rules Food and Drug Administration 21 CFR Part 1130 DocID: 1xVJS - View Document
	What is a Vulnerability Disclosure Policy and Why You Need One VDPs work and they protect assets. That’s why the U.S. Department of Justice, the European Commission, and the U.S. Food & Drug Administration recommend th DocID: 1xVfx - View Document
	Notice to Industry: Additional Tobacco Products Now Regulated by the Food and Drug Administration DocID: 1xVey - View Document
	DEPARTMENT OF HEALTH AND HUMAN S ERVICES _________________________________________________________________________________________________________ Food and Drug Administration Center for T obacco Products 9200 Corporate DocID: 1xUvW - View Document
	DEPARTMENT OF HEALTH AND HUMAN SERVICES _________________________________________________________________________________________________________ Food and Drug Administration Center for Tobacco ProductsNew Hampshi DocID: 1xTPU - View Document